WIN 2022 Program

INTEGRATING GENOMICS AND TRANSCRIPTOMICS TO RESHAPE PRECISION ONCOLOGY:
A WINNING STRATEGY

Monday March 14, 2022

WELCOME AND OPENING REMARKS

 

Welcome and Opening Remarks

Richard L. Schilsky

Chairman WIN Consortium, Villejuif, France

Josep Tabernero

Vice-Chairman WIN Consortium, Villejuif, France
Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain

 

Opening Keynote Lecture

Re-imagining the (r)evolution in the Precision Oncology paradigm: the future is now

Vivek Subbiah

The University of Texas, MD Anderson Cancer Center, Houston, USA

SESSION 1 - BEYOND DNA TESTING: THE PLACE OF TRANSCRIPTOMICS IN PRECISION ONCOLOGY

 

 

Keynote Lecture

Expression profiling to discover molecularly and clinically distinct cancer subtypes and to predict response to therapy

Louis M. Staudt

National Cancer Institute (NCI), Bethesda, USA

 

Keynote Lecture

Functional genomics to identify cancer vulnerabilities

René Bernards

Netherlands Cancer Institute (NKI), Amsterdam, Netherlands

 

Accelerating precision oncology using multi-omics and AI

Olivier Elemento

Weill Cornell Medicine, New York, USA

 

Coffee break, networking

 

Modeling gene regulatory processes to understand cancer and identify therapies

John Quackenbush

Harvard T.H. Chan School of Public Health, Boston, USA

   

Vladimir Lazar

WIN Consortium, Villejuif, France

 

Harnessing a synthetic lethality analysis for patient stratification: key role of transcriptomics

Eytan Ruppin

National Institute of Health (NIH), Bethesda, USA

 

Panel Discussion

 

Lunch, poster viewing and networking

SESSION 2 – INNOVATION IN CLINICAL TRIALS TO ENABLE FUTURE EFFICIENT TREATMENTS

 

Keynote opening Lecture

Bringing single cell analyses to the clinics

Andrea Califano

Columbia University Medical Center, New York, USA

 

Keynote lecture

Identifying new uses for approved, targeted drugs: Updates from the ASCO TAPUR study

Richard L. Schilsky

WIN Consortium, Villejuif, France

 

Genomic and transcriptomic signatures and innovation in CRC
cancers

Josep Tabernero

Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain

 

Phase 3 trial of adjuvant sunitinib in patients with high-risk renal cell carcinoma: comprehensive tumor genomic and transcriptomic analyses

Jean-François Martini

Pfizer, Inc., San Diego, USA

 

Patient stratification/selection for treatments with Tepotinib in
the era of personalized medicine

Ilhan Celik

Merck KGaA, Darmstadt, Germany

 

Coffee break, networking

 

Satellite Symposium

 

Poster viewing

Welcome Reception

          

Symposium Dinner

 

Download the WIN 2022 Program

Download the Program Here

WIN 2022 Symposium
c/o MCI UK Ltd
Durford Mill
Petersfield
GU31 5AZ

Tel: +44 (0) 1730 715223
General enquiries: winsymposium@mci-group.com
Sponsorship enquiries: winsymposium@mci-group.com
Abstract enquiries: winsympabstracts@mci-group.com
Registration enquiries: winsympreghot@mci-group.com

View Our Privacy Policy Here